GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ion Beam Applications SA (OTCPK:IOBCF) » Definitions » Debt-to-EBITDA

Ion Beam Applications (Ion Beam Applications) Debt-to-EBITDA : 0.76 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Ion Beam Applications Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ion Beam Applications's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.7 Mil. Ion Beam Applications's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.6 Mil. Ion Beam Applications's annualized EBITDA for the quarter that ended in Dec. 2023 was $59.6 Mil. Ion Beam Applications's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.76.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ion Beam Applications's Debt-to-EBITDA or its related term are showing as below:

IOBCF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.61   Med: 2.17   Max: 12.19
Current: 2.53

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ion Beam Applications was 12.19. The lowest was -2.61. And the median was 2.17.

IOBCF's Debt-to-EBITDA is ranked worse than
66.98% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.245 vs IOBCF: 2.53

Ion Beam Applications Debt-to-EBITDA Historical Data

The historical data trend for Ion Beam Applications's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ion Beam Applications Debt-to-EBITDA Chart

Ion Beam Applications Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.62 1.80 3.34 3.31 2.53

Ion Beam Applications Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 3.82 5.29 -1.91 0.76

Competitive Comparison of Ion Beam Applications's Debt-to-EBITDA

For the Medical Devices subindustry, Ion Beam Applications's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ion Beam Applications's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ion Beam Applications's Debt-to-EBITDA falls into.



Ion Beam Applications Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ion Beam Applications's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(13.711 + 31.636) / 17.932
=2.53

Ion Beam Applications's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(13.711 + 31.636) / 59.6
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Ion Beam Applications  (OTCPK:IOBCF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ion Beam Applications Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ion Beam Applications's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ion Beam Applications (Ion Beam Applications) Business Description

Traded in Other Exchanges
Address
Chemin du Cyclotron, 3, Louvain-La-Neuve, BEL, B-1348
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World, with REst-of-World sales generating the largest proportion of revenue.

Ion Beam Applications (Ion Beam Applications) Headlines

From GuruFocus

Q2 2023 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2019 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2019 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Ion Beam Applications SA Earnings Call Transcript

By GuruFocus Research 02-14-2024